Sa1648: A PROBIOTIC FORMULA (SMT04) FOR MODULATION OF COLORECTAL CANCER RISK VIA REDUCING CRC-ASSOCIATED BACTERIAL GENE MARKERS

Liang, Jessie Qiaoyi; Yao, Zhen; Xu, Zhi Lu; Ng, Siew C.; Chan, Francis Ka‐Ming

doi:10.1016/s0016-5085(22)61075-8

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously this combination has been shown to decrease the development of colorectal neoplasia and inhibit the growth of Fn in laboratory experiments [6]. This combination also reduced the abundance of CRC-associated bacterial DNA markers in human subjects when administered at a high dosage in our previous clinical trial.…”

Section: Discussionmentioning

confidence: 61%

“…For example, the level of bifidobac-teria decreased with colorectal neoplasia progression and was negatively correlated with CRC-enriched markers [5]. In vitro coculturing with individual bifidobacterium species significantly inhibited the growth of Fn compared with control (24~65% inhibition) [6]. A subsequent study reported that a combination of Bifidobacteria spp.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of a Novel Probiotic Formula (SMT04) in Reducing Colorectal CancerAssociated Biomarkers

2023

IJPD

View full text Add to dashboard Cite

Background and aims: Certain probiotic bacteria have been shown to reduce the risk of CRC in animal experiments. This pilot study aimed to determine the efficacy and safety of a novel probiotic formula, SMT04, which consists of Bifidobacterial and Streptococcus, in reducing CRC-associated bacterial pathogens in humans. Methods: This was a pilot study of subjects taking SMT04 for 3 months (50 billion CFU per sachet). Subjects aged 18 or above who underwent colonoscopy within one year were enrolled. Exclusion criteria included a history of CRC; severe co-morbidity; and use of probiotics, prebiotics, or antibiotics within 30 days. Subjects underwent a noninvasive stool test for the quantitation of three CRC-associated bacterial DNA markers (Fn, m3 and Ch) by qPCR according to a prespecified protocol at baseline, month 1, month 2, and month 3. The primary outcome was the change in CRC-associated bacterial DNA markers. Gastrointestinal symptoms and adverse events were assessed. All subjects provided informed written consent. Results: Twenty-one (M:F 9:11) eligible subjects were recruited (mean age ± SD: 56.57 ± 8.81). All 3 bacterial DNA markers at month 1, month 2, and month 3 decreased compared to baseline (Ch [-91.4846, -67.2877, and -83.3429]; Fn [-31.8973, -24.4503, and -22.7081]; m3 [-30.5499, -12.2656, and -37.3651]. There was an improvement in gastrointestinal symptoms. None experienced adverse events. Conclusion: SMT04 was effective in reducing CRC-associated bacterial DNA markers. This novel probiotic formula may potentially reduce the risk of CRC via modulation of gut microbiota.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

The Effect of a Novel Probiotic Formula (SMT04) in Reducing Colorectal CancerAssociated Biomarkers

2023

IJPD

View full text Add to dashboard Cite

show abstract

“…Each specific stain significantly inhibited growth of F. nucleatum and the combination of the three strains had a greater growth inhibition of 70%. [62] Collectively, the reduction of CRC-related markers and the enrichment in beneficial bacteria indicated the effects of probiotics in rebalancing the gut microbiota and reduce level of gut dysbiosis by metabolites production in CRC.…”

Section: Mechanisms Of Probiotics In Crc Prevention and Treatmentmentioning

confidence: 99%

Probiotics intervention in colorectal cancer: From traditional approaches to novel strategies

Ha,

Zhang,

2023

Chin Med J

View full text Add to dashboard Cite

The intestine harbors a large population of microorganisms that interact with epithelial cells to maintain host healthy physiological status. These intestinal microbiota engage in the fermentation of non-digestible nutrients and produce beneficial metabolites to regulate host homeostasis, metabolism, and immune response. The disruption of microbiota, known as dysbiosis, has been implicated in many intestinal diseases, including colorectal cancer (CRC). As the third most common cancer and the second leading cause of cancer-related death worldwide, CRC poses a significant health burden. There is an urgent need for novel interventions to reduce CRC incidence and improve clinical outcomes. Modulating the intestinal microbiota has emerged as a promising approach for CRC prevention and treatment. Current research efforts in CRC probiotics primarily focus on reducing the incidence of CRC, alleviating treatment-related side effects, and potentiating the efficacy of anticancer therapy, which is the key to successful translation to clinical practice. This paper aims to review the traditional probiotics and new interventions, such as next-generation probiotics and postbiotics, in the context of CRC. The underlying mechanisms of probiotic anti-cancer effects are also discussed, including the restoration of microbial composition, reinforcement of gut barrier integrity, induction of cancer cell apoptosis, inactivation of carcinogens, and modulation of host immune response. This paper further evaluates the novel strategy of probiotics as an adjuvant therapy in boosting the efficacy of chemotherapy and immunotherapy. Despite all the promising findings presented in studies, the evaluation of potential risks, optimization of delivery methods, and consideration of intra-patient variability of gut microbial baseline must be thoroughly interpreted before bench-to-bedside translation.

show abstract

“…Pro- and prebiotica gained a lot of attention from the lay public due to their alleged health-promoting effects, but while they are admitted as food supplements, their use in the clinical setting is not approved and a beneficial effect for cancer patients is uncertain. Regarding probiotics, there is evidence that probiotic formulations containing Lactobacilli and Bifidobacteria might reduce tumor burden in mouse and rat models of colitis-associated CRC [35], and probiotica might reduce the abundance of bacterial strains that are generally associated with cancer development [36]. Further, it has been shown that some probiotics might reduce side effects of chemo- and radiotherapy [35].…”

Section: The Use Of Probiotica and Prebiotica In Cancer Patientsmentioning

confidence: 99%

Microbiota Manipulation as an Emerging Concept in Cancer Therapy

Spalinger,

Scharl

2023

Visc Med

View full text Add to dashboard Cite

Background: The human body is colonized by billions of bacteria that provide nutrients to the host, train our immune system, and importantly affect our heath. It has long been suggested that microbes might play a role in tumor pathogenesis; however, compelling evidence was only provided in the past decades when novel detection methods that do not depend on culturing techniques had been developed. Summary: The microbiome impacts tumor development and anti-tumor therapies on various levels. Bacteria can promote or suppress tumor growth via direct interactions with cancer cells, production of metabolites that promote or inhibit tumor growth, and via stimulation or suppression of the local and systemic immune response. Cancer patients harbor a distinct microbiome when compared to healthy controls, which could potentially be employed to detect, identify, and treat cancer. Manipulation of the microbiome either via supplementation of single strains, bacterial consortia, fecal microbiota transfer or the use of pre- and probiotics has been suggested as therapeutic approach to directly target tumor growth or to enhance the efficacy of current state-of-the-art treatment options. Key Messages: (1) Bacteria have a tremendous impact on anti-cancer immune responses. (2) Cancer patients harbor a distinct microbiome when compared to healthy controls. (3) The microbiome seems to be cancer-type specific. (4) Exploitation of bacteria to promote anti-tumor therapy is a novel, very promising venue in cancer treatment.

show abstract

Sa1648: A PROBIOTIC FORMULA (SMT04) FOR MODULATION OF COLORECTAL CANCER RISK VIA REDUCING CRC-ASSOCIATED BACTERIAL GENE MARKERS

Cited by 3 publications

References 0 publications

The Effect of a Novel Probiotic Formula (SMT04) in Reducing Colorectal CancerAssociated Biomarkers

The Effect of a Novel Probiotic Formula (SMT04) in Reducing Colorectal CancerAssociated Biomarkers

Probiotics intervention in colorectal cancer: From traditional approaches to novel strategies

Microbiota Manipulation as an Emerging Concept in Cancer Therapy

Contact Info

Product

Resources

About